Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 3 | $2.46 | $2.47 | $2.47 |
Q2 2024 | 4 | $2.74 | $2.74 | $2.74 |
Q3 2024 | 8 | $1.36 | $1.48 | $1.42 |
Q4 2024 | 14 | $5.37 | $5.58 | $5.49 |
Q1 2025 | 1 | $4.98 | $5.22 | $5.15 |
Q2 2025 | 1 | $5.31 | $5.56 | $5.48 |
Q3 2025 | 1 | $5.51 | $5.77 | $5.69 |
Q4 2025 | 1 | $3.17 | $3.32 | $3.28 |
Eli Lilly and Company last posted its earnings results on Wednesday, October 30th, 2024. The company reported $1.18 earnings per share for the quarter, missing analysts' consensus estimates of $1.47 by $0.29. The company had revenue of 11.44 B for the quarter and had revenue of 34.12 B for the year. Eli Lilly and Company has generated $6 earnings per share over the last year ($5.8 diluted earnings per share) and currently has a price-to-earnings ratio of 82.65. Eli Lilly and Company has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 6th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
10/30/2024 | Q3 2024 | $1.47 | $1.08 | -0.39 | $12.10 B | $11.44 B |
08/08/2024 | Q2 2024 | $2.60 | $3.29 | 0.69 | $9.98 B | $11.30 B |
04/30/2024 | Q1 2024 | $2.46 | $2.49 | 0.03 | $8.77 B | |
02/21/2024 | Q4 2023 | $2.31 | $9.35 B | |||
11/02/2023 | Q3 2023 | -$0.08 | -$0.06 | 0.02 | $8.97 B | $9.50 B |
08/08/2023 | Q2 2023 | $1.98 | $1.96 | -0.02 | $7.58 B | $8.31 B |
04/27/2023 | Q1 2023 | $1.73 | $1.49 | -0.24 | $6.96 B | |
02/22/2023 | Q4 2022 | $2.04 | $7.30 B | |||
11/01/2022 | Q3 2022 | $1.92 | $1.61 | -0.31 | $6.89 B | $6.94 B |
08/04/2022 | Q2 2022 | $1.69 | $1.06 | -0.63 | $6.85 B | $6.49 B |
04/29/2022 | Q1 2022 | $2.11 | $7.81 B | |||
02/23/2022 | Q4 2021 | $1.81 | $8.00 B | |||
10/27/2021 | Q3 2021 | $1.22 | $6.64 B | $6.77 B | ||
08/03/2021 | Q2 2021 | $1.89 | $1.53 | -0.36 | $6.60 B | $6.74 B |
04/30/2021 | Q1 2021 | $1.49 | $6.81 B | |||
02/17/2021 | Q4 2020 | $2.21 | $7.44 B | |||
10/28/2020 | Q3 2020 | $1.33 | $5.88 B | $5.74 B | ||
07/31/2020 | Q2 2020 | $1.56 | $5.76 B | $5.50 B | ||
05/01/2020 | Q1 2020 | $1.60 | $5.86 B | |||
02/19/2020 | Q4 2019 | $1.56 | $6.11 B |
Eli Lilly and Company has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 6th, 2025 based off last year's report dates.
The conference call for Eli Lilly and Company's latest earnings report can be listened to online.
The conference call transcript for Eli Lilly and Company's latest earnings report can be read online.
Eli Lilly and Company (:LLY) has a recorded annual revenue of $34.12 B.
Eli Lilly and Company (:LLY) has a recorded net income of $34.12 B. Eli Lilly and Company has generated $5.8 earnings per share over the last four quarters.
Eli Lilly and Company (:LLY) has a price-to-earnings ratio of 82.65 and price/earnings-to-growth ratio is 5.82.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED